AUROBAC THERAPEUTICS

Name

AUROBAC THERAPEUTICS

Legal name

AUROBAC THERAPEUTICS SAS

Website

https://aurobac-tx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

AUROBAC THERAPEUTICS is a clinical-stage biopharmaceutical company developing precision medicines to fight antimicrobial resistance, with a lead host-targeted sepsis program (ATX101) partnered with Boehringer Ingelheim. Founded in 2022 by Boehringer Ingelheim, Evotec, and bioMérieux and headquartered in Lyon, the company targets hospitals and intensive care units treating severe bacterial infections, HAP/VAP, sepsis, and septic shock.

Ownership category

akta.pro rank

Product category

Anti-Infective Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAAAG

Infectious Disease & Antimicrobials Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAM

Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIALAH

Regulatory Strategy & IND/NDA/BLA Submissions Support

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAGAEAD

Genomics & Molecular Diagnostics (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

• Antimicrobial resistance therapeutics
• Sepsis drug development
• Gram-negative infection medicines
• Biopharmaceutical precision medicines
• Hospital-acquired infection therapies

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: As a biopharmaceutical company developing novel drugs, AUROBAC's primary expected revenue stream will come from commercialization of pipeline products (ATX101, ATX5) for treatment of sepsis, septic shock, and Gram-negative bacterial infections. The company aims to cover the entire value chain from research and development through clinical trials, registration, and commercialization.
2. Licensing and Partnership Agreements: AUROBAC pursues various partnership agreements including R&D consortiums, academic cooperation, co-development arrangements, licensing agreements, and potential full acquisitions. The company leverages support from founding organizations (Boehringer Ingelheim, bioMérieux, Evotec) to bring innovative products to market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

AUROBAC THERAPEUTICS develops novel chemical entities — led by ATX101 (a first-in-class host-targeted treatment for sepsis and septic shock that completed Phase 1 in March 2026) and ATX5 (a discovery-stage program against Gram-negative pathogens) — that address both the causes and consequences of severe bacterial infections and antimicrobial resistance in acute hospital settings. The pipeline is supported by a Drug Discovery Engine and a diagnostic-driven precision medicine strategy pairing therapeutics with rapid patient-stratification diagnostics.

Product overview

AUROBAC THERAPEUTICS is a biopharmaceutical company developing a pipeline of precision medicines targeting severe bacterial infections and antimicrobial resistance (AMR). The product portfolio consists of ATX101 (a first-in-class host-targeted new chemical entity for sepsis and septic shock, partnered with Boehringer Ingelheim, currently in Phase 1 completed), ATX5 (a MedChem program for Gram-negative pathogens in hit-to-lead stage), and a Drug Discovery Engine that integrates strategic partnerships to identify novel antimicrobial agents. The company focuses on patient- and pathogen-targeted programs for hospital-acquired infections, ventilator-associated pneumonia, and sepsis.

Differentiator

Problem solved

Functional benefit

Products and services

• ATX101 First-in-class host-targeted new chemical entity designed to address the pathophysiological mechanisms of sepsis and septic shock, with the target indication being treatment of early septic shock to prevent progression and improve outcomes. Partnered with Boehringer Ingelheim.
• ATX5 New chemical entity in a MedChem program targeting an undisclosed mechanism for the treatment of infections caused by Gram-negative pathogens. Currently in hit-to-lead stage as part of AUROBAC's Drug Discovery Engine hit discovery programs.

Quantifiable outcome

• Phase 1 clinical trial successfully completed for ATX101 in March 2026 (ClinicalTrials.gov NCT07107802)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered founding/core and minor.

• Boehringer Ingelheimfounding/coreStrategic or Co-development Partner · 3 June 2024New collaboration and license agreement on a Boehringer Ingelheim compound developed as ATX101 for treatment of septic shock. The strategic partnership with Boehringer Ingelheim reflects 'shared commitment to developing innovative therapies to tackle urgent unmet medical needs in patients in critical care settings.' Phase 1 trial completion (March 2026) 'reflects the strength of its strategic partnership with Boehringer Ingelheim.'
• Boehringer Ingelheimfounding/coreStrategic or Co-development Partner · 1 January 2022Boehringer Ingelheim is a founding organization of AUROBAC THERAPEUTICS (established 2022). The partnership includes collaboration on ATX101 development - Boehringer Ingelheim contributed a compound licensed to AUROBAC for septic shock treatment development. AUROBAC's headquarters is located within Boehringer Ingelheim's building in Lyon. Frank Kalkbrenner represented Boehringer Ingelheim as former Chairman of the Board. ATX101 clinical trial collaboration mentioned as 'strong and productive collaboration with Boehringer Ingelheim' for developing innovative therapies for critical care settings.
• bioMérieuxfounding/coreStrategic or Co-development Partner · 1 January 2022bioMérieux is a founding organization of AUROBAC THERAPEUTICS (established 2022). The company brings diagnostic capabilities supporting AUROBAC's diagnostic-driven precision medicine strategy. François Lacoste, DVM represents bioMérieux on AUROBAC's Board of Directors. The combination of pharma (Boehringer Ingelheim), diagnostics (bioMérieux), and drug discovery (Evotec) capabilities forms the foundation of AUROBAC's strategic approach.
• Evotec SEfounding/coreStrategic or Co-development Partner · 1 January 2022Evotec is a founding organization of AUROBAC THERAPEUTICS (established 2022). The company provides drug discovery capabilities including the 'Drug Discovery Engine' that integrates strategic partnerships to efficiently identify and advance novel antimicrobial agents. Antonio Felici, Ph.D. represents Evotec on AUROBAC's Board of Directors.
• BEAM AllianceminorOthersAUROBAC THERAPEUTICS is a member of the BEAM Alliance (Biomedicines for Antimicrobial Resistance). BEAM Alliance is a European alliance of companies developing antimicrobials, antibiotics, alternatives to antibiotics, and diagnostics for human health. CEO Florence Séjourné represents AUROBAC and BEAM Alliance at industry events including World Health Summit 2024.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• BioVersys: Swiss clinical-stage biopharmaceutical company developing small molecule drugs to fight antimicrobial resistance, with a focus on hospital-acquired infections and ESKAPE pathogens. Directly comparable as a European AMR-focused biotech with similar therapeutic focus, pipeline stage, and BEAM Alliance membership.
• Entasis Therapeutics: Clinical-stage biopharmaceutical company developing targeted therapies for drug-resistant bacterial infections, including Gram-negative pathogens. Highly comparable focus on AMR, precision medicine approaches, and similar development stage; acquired by Innoviva in 2022.
• Iterum Therapeutics: Clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, with focus on Gram-negative infections and oral and IV antibiotics. Directly comparable as a clinical-stage anti-infective company targeting similar pathogens and hospital-acquired infections.
• Cidara Therapeutics: Clinical-stage biotechnology company developing novel anti-infectives including immunotherapies for serious infections. Comparable as a clinical-stage anti-infective biotech targeting serious bacterial and fungal infections in hospital settings.
• Melinta Therapeutics: Commercial-stage pharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Comparable as an antibiotics-focused company targeting multi-drug resistant infections in hospital settings; emerged from bankruptcy in 2020.
• Paratek Pharmaceuticals: Commercial-stage biopharmaceutical company developing and commercializing novel antibiotics for serious community-acquired and hospital-acquired bacterial infections. Comparable focus on antibacterial innovation and similar therapeutic indications including pneumonia; acquired by Gurnet Point in 2023.
• VenatoRx Pharmaceuticals: Private clinical-stage pharmaceutical company developing novel therapies to treat drug-resistant bacterial infections, particularly Gram-negative ESKAPE pathogens. Comparable as a clinical-stage antibiotics developer targeting multi-drug resistant Gram-negative infections.
• Tetraphase Biosciences: Biopharmaceutical company (acquired by La Jolla Pharmaceutical in 2020) that developed XERAVA, a novel antibiotic for complicated intra-abdominal infections caused by resistant bacteria. Comparable antibiotics developer with focus on multi-drug resistant bacterial infections.

Broad incumbents

• Innoviva (Entasis parent): Diversified specialty pharmaceutical company that acquired Entasis Therapeutics in 2022 to add a clinical-stage anti-infective franchise targeting AMR. Comparable through its anti-infective subsidiary addressing drug-resistant infections.
• Shionogi: Japanese pharmaceutical company with a strong anti-infectives franchise including cefiderocol (FETROJA), an antibiotic targeting multi-drug resistant Gram-negative infections including those causing HAP/VAP and sepsis. Comparable through its late-stage antibacterial portfolio addressing AMR in hospital settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aurobac-tx
• Xx.com/AurobacTX

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AUROBAC THERAPEUTICS